"El Instituto de Investigaciones Clínicas Quilmes SRL es una institución abocada exclusivamente a la realización de estudios clínicos ambulatorios, en fase II, III y IV. Con una vasta experiencia del staff en estudios cardiológicos, reumatológicos, oncológicos y en diabetes, tanto en pacientes internados como ambulatorios. Así como entrenamiento y capacitación continua en el área de ensayos clínicos."

During the past decade, Instituto de Investigaciones Clinicas Quilmes conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 16 clinical trials were completed, i.e. on average, 84.2% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 13 clinical trials were completed. i.e. 144.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Investigaciones Clinicas Quilmes" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 3 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Investigaciones Clinicas Quilmes" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "OCT Clinical Trials" with 2 trials as a collaborator and "ARTTIC International Management Services" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Investigaciones Clinicas Quilmes" are "Rheumatoid Arthritis" (5 trials), "Systemic Lupus Erythematosus" (4 trials), "Pulmonary Arterial Hypertension" (3 trials), "Heart Failure" (2 trials) and "Hypertension" (2 trials). Many other conditions were trialed in "Instituto de Investigaciones Clinicas Quilmes" in a lesser frequency.

Most popular intervention types in "Instituto de Investigaciones Clinicas Quilmes" are "Drug" (24 trials), "Other" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Baricitinib" (3 trials), "Sotatercept" (3 trials), "Darusentan" (2 trials) and "Empagliflozin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Investigaciones Clinicas Quilmes" are 26 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Instituto de Investigaciones Clinicas Quilmes". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Instituto de Investigaciones Clinicas Quilmes, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Investigaciones Clinicas Quilmes, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".